To Evaluate 2 Doses of GSK Biologicals’ Oral Live Attenuated Human HRV Vaccine co-Administered With Either OPV or IPV

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00346892
First received: February 3, 2006
Last updated: September 22, 2006
Last verified: September 2006
  Purpose

"The primary objective of this study was to demonstrate that co-administering HRV vaccine with OPV does not induce a significant decrease in poliovirus immune response one month after the third dose of combined vaccines.

The primary objective was reached if one month after the third dose of polio vaccine, upper limit of the 95% CI for the difference in Seroprotection rate between the group B and C pooled and (minus) the group A was below 10% for each polio serotype."


Condition Intervention Phase
Rotavirus Infections
Biological: Rotavirus (vaccine)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Reactogenicity & Immunogenicity Study of Two Doses of GSK Biologicals’ Oral Live Attenuated HRV Vaccine co-Administered With Either OPV or IPV in Healthy Infants (Approximately 5-10 Weeks Old) in South Africa

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Seroprotection for each polio serotype 1 month after the 3rd dose.

Secondary Outcome Measures:
  • Proportion of subjects with vaccine take 1 month after each dose of study vaccine, viral shedding in a subset of subjects, presence of RV in diarrheal stools, anti-rota IgA antibody seroconversion rate and serum anti-rota IgA antibody concent

Estimated Enrollment: 450
Study Start Date: November 2001
Detailed Description:

The study had three groups: Group A: HRV + OPV + DTPa/Hib; Group B: HRV + placebo OPV + DTPa-IPV/Hib; Group C: HRV Placebo + OPV + DTPa/Hib. Two cohorts: Subjects enrolled before the 2002 RV season were to receive two doses of HRV or placebo at approximately 6 and 10 weeks of age (first cohort) and subjects enrolled after the 2002 RV season received vaccinations at approximately 10 and 14 weeks of age (second cohort). Routine EPI vaccinations were to be administered concomitantly with the study vaccines.

  Eligibility

Ages Eligible for Study:   5 Weeks to 10 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria: Healthy infants between 5 and 10 weeks of age at first study vaccination with (after the 2002 RV season) confirmed negative HIV status of the subject’s mother during pregnancy or thereafter. Exclusion criteria: History of allergic disease, any confirmed or suspected immunosuppressive or immunodeficient condition, clinically significant history of chronic gastrointestinal disease or other serious medical condition as determined by the investigator or had not received treatment prohibited by the protocol.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00346892

Locations
South Africa
Pretoria, South Africa
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: Clinical Trials GlaxoSmithKline
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00346892     History of Changes
Other Study ID Numbers: 444563/014
Study First Received: February 3, 2006
Last Updated: September 22, 2006
Health Authority: South Africa: Medicines Control Council

Keywords provided by GlaxoSmithKline:
Prophylaxis rotavirus

Additional relevant MeSH terms:
Rotavirus Infections
Reoviridae Infections
RNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on April 16, 2014